Tuesday, 8 April 2008

Reprogrammed Cells Reduce Parkinson's Symptoms in Rats

Dopamine-producing neurons transplanted into adult rat brains treat behavioural symptoms related to low dopamine levels Tuesday, 08 April 2008 Neurons derived from reprogrammed adult skin cells successfully integrated into foetal mouse brains and reduced symptoms in a Parkinson’s disease rat model, according to a study published on April 7 in the online Early Edition of PNAS. “This is the first demonstration that reprogrammed cells can integrate into the neural system or positively affect neurodegenerative disease,” says Marius Wernig, lead author of the article and a postdoctoral researcher in Whitehead Institute for Biomedical Research member Rudolph Jaenisch’s lab. Researchers in the Jaenisch lab showed in December 2007 that mice with a human sickle-cell anaemia disease trait could also be treated successfully with adult skin cells that had been reprogrammed to an embryonic stem cell-like state. For the neural experiments Wernig used induced pluripotent stem cells (IPS cells), which were created by reprogramming adult skin cells using retroviruses to express four genes (Oct4, Sox2, c-Myc and Klf4) into the cells’ DNA. The IPS cells were then differentiated into neural precursor cells and dopamine neurons using techniques originally developed in embryonic stem cells. In one experiment, Wernig transplanted the neural precursor cells into brain cavities of mouse embryos. The mice were naturally delivered and analyzed nine weeks after the transplantation. Wernig saw that transplanted cells formed clusters where they had been injected and then migrated extensively into the surrounding brain tissues. Using electrophysiological studies conducted by Martha Constantine-Paton from MIT’s McGovern Institute for Brain Research and structural analysis, Wernig also saw that the neural precursor cells that migrated had differentiated into several subtypes of neural cells, including neurons and glia, and had functionally integrated into the brain. The cells "migrate nicely into the brain and mature in the brain," says Marius Wernig. "They adopt functions of mature neurons." To assess the therapeutic potential of the IPS cells, the Jaenisch lab collaborated with Ole Isacson's group at Mclean Hospital/Harvard Medical School and used a rat model for Parkinson's disease, a human condition caused by insufficient levels of the hormone dopamine in a specific part of the midbrain. To mimic this state, the dopamine-producing neurons were killed on one side of the rat brains and the researchers then grafted differentiated dopamine neurons into a part of the rat brains called the striatum. Four weeks after surgery, the rats were tested for dopamine-related behaviour. In response to amphetamine injections, rats typically walk in circles toward the side with less dopamine activity in the brain. Eight of nine rats that received the dopamine neuron transplants showed markedly less or even no circling. Eight weeks after transplantation, the researchers could see that the dopamine neurons had extended into the surrounding brain. “This experiment shows that in vitro reprogrammed cells can in principle be used to treat Parkinson’s disease,” says Jaenisch. “It’s a proof of principle experiment that argues, yes, these cells may have the therapeutic promise that people ascribe to them.” For many years, a small group of patients with Parkinson's disease have received experimental cell transplants using dopamine neurons derived from foetuses. But the use of foetal tissue poses ethical and logistical hurdles for widespread use. Scientists have performed similar experiments in animals using stem cells derived from embryos or created with nuclear transfer, also known as therapeutic cloning. But iPS cells offer a way to avoid the use of embryos as well as the technical challenges of nuclear transfer. And if the cells came from a patient's own skin, there would be no potential complications from immune rejection of foreign tissue. When the team first performed the experiment, many rats developed tumours, which seemed to arise from the fact that not all of the iPS cells had fully transformed into neurons when they were transplanted. Tumours such as these have also been observed in experiments with embryonic stem cells. In this study, however, the researchers performed another set of transplants, first using a cell-sorting method that can identify and remove any cells that have failed to differentiate. "When we eliminated the undifferentiated cells from mixture, we got very clean transplants," says Ole Isacson, a neurologist at Harvard Medical School who collaborated on the transplant experiments. The rats given these purified cells did not go on to develop tumours. He believes that the varying purity of transplants may prove to be a key factor in why some of the foetal cell transplants have not succeeded as well as others. Jaenisch and Wernig are optimistic that this work eventually could be applied to human patients, but caution that major hurdles must be addressed first. Those include finding alternatives to the potentially cancer-causing retroviruses used to transform the skin cells into IPS cells and figuring out the best methods and places to transplant the neural precursor cells in humans. Reference: Neurons derived from reprogrammed fibroblasts functionally integrate into the fetal brain and improve symptoms of adult rats with Parkinson’s Marius Wernig, Jian-Ping Zhao, Jan Pruszak, Eva Hedlund, Dongdong Fu, Frank Soldner, Vania Broccoli, Martha Constantine-Paton, Ole Isacson, Rudolf Jaenisch Proc. Natl. Acad. Sci. USA, 10.1073/pnas.0801677105 ......... ZenMaster

For more on stem cells and cloning, go to CellNEWS at http://www.geocities.com/giantfideli/index.html

1 comment:

Anonymous said...

Thanks for the post on PD. There is new hope on the horizon with cell transplantation -- and not just the traditional stem cells. The exciting discovery of radial glia-like cells that lead to the production of dopaminergic neurons in the midbrain may pose a potential source for cell transplants in Parkinson's disease. We recently wrote on this issue at Brain Blogger.

I would like to read your commentary on our website. Thank you.